Lantheus PE ratio LNTH

Share price divided by earnings per share over the last twelve months, since 2016.

Today, Oct 23, 2026: 24.2×
10-year median: 24.0×
Against its 10-year history: 52nd; percentile: 0 is its lowest day, 100 its highest
10-year range: 9.2× to 267×
Peer median: 38.4×

Lantheus' PE ratio is 24.2× as of Oct 23, 2026: a share price of $99.80 against $4.13 of earnings per share over the last twelve months.

That is above its ten-year median of 24.0×, close to the middle of its last ten years.

Over that time it ranged from 9.2× in Oct 2016 to 267× in Apr 2023.

The median for 10 diagnostics and research stocks of a similar size is 38.4×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	24.2×	21.6×	31.0×
2025	28.0×	13.0×	28.0×
2024	15.3×	11.5×	45.1×
2023	43.4×	32.5×	267×
2022	34.2×	34.0×	198×
2021	242×	185×	250×
2020	169×	13.1×	186×
2019	23.3×	19.1×	26.6×
2018	24.4×	24.4×	29.1×
2017	25.2×	9.8×	32.0×
2016	10.2×	6.7×	11.7×

Against its peers

Companies in Medical - Diagnostics & Research nearest Lantheus' size, closest first, today.

Company	PE ratio
LNTHLantheus	24.2×
BLLNBillionToOne	166×
CAICaris Life Sciences	86.5×
BIOBio-Rad Laboratories	44.8×
VCYTVeracyte	34.2×
CDNACareDx	33.4×
RVTYRevvity	75.6×
MEDPMedpace	39.2×
LHLabcorp	27.2×
DGXQuest Diagnostics	25.7×
MTDMettler-Toledo International	37.6×
Peer median	38.4×

Where Lantheus ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Lantheus

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.